MedTech Metro
Add to calendar
Thursday, September 17, 2015
5:30 pm – 9:00 pm
Location: Loeb & Loeb, 345 Park Ave, New York, NY 10154
MedTech Metro is an intimate forum and networking series designed to showcase New York’s bioscience and medical technology (Bio/Med) community before an audience of investors, business leaders and health care providers committed to promoting and supporting the Bio/Med industry.
Agenda:
- 5:30 - Registration
- 6:00 - Cocktail Reception
- 7:00 - Company Presentations
- 7:45 - Panel Discussion
Title: The State of Change: Evolution of Today’s Life Sciences Industry
The way good science becomes good medicine has dramatically changed over the past several years. Industry focus, in part, has shifted from small molecules to big devices; from in-house R&D to mergers and acquisitions; from fee for service to fee for value. Through actions on Wall Street, in the FDA, the White House and beyond, the evolving healthcare landscape is evident. Join us for a discussion from top executives and industry leaders on innovative business in our ever-changing life sciences industry.
- 8:45 - Networking
Panelists
- Moderator - Scott Liebman, Partner, Loeb & Loeb
- Panelist - Scott Gucciardi, Senior Vice President and General Manager of Healthcare and Delivery Solutions, Welch Allyn
- Panelist - Scott Livingston, Chairman and Chief Executive Officer, Livingston Securities
Presenting Companies
6Degrees
- Presenter - Aryeh Katz, Co-founder
- Presenter - Miri Berger, Co-founder
-
The team at 6Degrees is developing a wearable device that allows amputees and others with upper limb deficiency (carpal tunnel, stroke-related paralysis, Parkinson's disease, etc) to operate computer keyboards, smartphones, tablets and other Bluetooth-enabled products, with intuitive ease. The patented technology converts limb motion into electronic commands, opening a path for people with physical disability to join the world of Computer and Cyber technology. Self founded till now, they are looking for investments in order to move the project into its next phase and partners with experience in the field.
Allovate
- Presenter - Erick Berglund, Chief Executive Officer
-
Allovate, LLC is a specialty biopharmaceutical company that is developing an improved approach to allergen-specific immunotherapy for treating allergic diseases. Allovate's lead product is Allerdent™, a platform for improved, patient-friendly allergen-specific immunotherapy (AIT). AIT is a disease-modifying treatment that addresses the underlying causes of allergic disorders including allergic rhinitis, atopic dermatitis, and asthma. The core of the Allerdent™ platform is a specially formulated, fully customizable toothpaste designed to deliver oral mucosal immunotherapy (OMIT) while a user brushes their teeth. Allerdent™ integrates allergy treatment into a patient’s everyday routine while targeting the regions of the mouth most important for reducing allergic sensitization. It is currently available without active pharmaceutical ingredients for use as part of physicians’ existing immunotherapy protocols. Allovate is now raising a bridge round of financing and will be launching a Series A in October 2015 to support clinical research on a pharmacologically standardized, FDA-approved Allerdent™ formulation.
Ichor Therapeutics, Inc
- Presenter - Kelsey Moody, Chief Executive Officer
-
Ichor Therapeutics is developing an enzyme augmentation therapy to treat dry and wet forms of age-related macular degeneration (AMD), the leading cause of vision loss in persons over the age of 50. The technology platform is also expected to have secondary applications for several orphan diseases, including Stargardt’s macular degeneration. Founded in the living room apartment of then-medical student Kelsey Moody, the company has since raised over $1.2 million in non/minimally-dilutive funding and has completed a MTTR agreement with SENS Research Foundation to develop and commercialize this technology. Ichor is seeking to raise $450k in dilutive funding to develop, characterize, and manufacture its portfolio of candidate enzymes. These funds will also support pilot murine studies to assess acute and chronic toxicity, immunogenicity, and efficacy, substantially de-risking pre-IND GLP studies.